HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risking FTC Scrutiny, Direct Seller Ignores Industry Self-Regulation Group On COVID-19 Claims

Executive Summary

Direct seller Flavon USA is referred to FTC after it failed to respond to repeated outreach by Direct Selling Self-Regulatory Council over claims its supplements treat coronavirus. The watchdog asked for substantiation of claims suggesting products also could tumors and diabetes.

You may also be interested in...



UK Researchers Seek Commercial Partner For Nasal Spray Shown To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Immunity, Weight Loss Supplement Marketers Risk FTC Scrutiny By Ignoring Industry Self-Regulation

NAD forwards to regulatory agency its concerns about claims by Hypernatural and Letitox Nutrition after they didn’t participate in the industry self-regulation forum. Both firms’ claims were challenged by the Council for Responsible Nutrition as part of a program with NAD it previously supported.

Direct Sales Industry Guidance Responds To ‘Increase In Questionable Earnings Claims’

Direct Selling Self-Regulatory Council and Direct Selling Association guidance aims to curb multi-level marketers’ misleading earnings claims, a practice increasing among health and wellness direct sellers during the COVID-19 pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel